Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.23−0.04 (-1.76%)
Close on Nov 13, 2026Market cap $3.37MP/E –Yield –
Apimeds Pharmaceuticals US cash
Cash and short-term investments held at the end of each period.
Apimeds Pharmaceuticals US's cash was $278.37K at Jun 30, 2026. For fiscal 2025 it was $3.64M, up 105157.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.64M | +105157.7% |
| FY2024 | Dec 31, 2024 | $3.46K | -99.2% |
| FY2023 | Dec 31, 2023 | $410.48K | +6551.8% |
| FY2022 | Dec 31, 2022 | $6.17K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $278.37K | -96.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.48M | +890.1% |
| Q4 FY2025 | Dec 31, 2025 | $3.64M | +105157.7% |
| Q3 FY2025 | Sep 30, 2025 | $6.99M | +26194.1% |
| Q2 FY2025 | Jun 30, 2025 | $8.74M | +13694.2% |
| Q1 FY2025 | Mar 31, 2025 | $250.43K | +69.9% |
| Q4 FY2024 | Dec 31, 2024 | $3.46K | -99.2% |
| Q3 FY2024 | Sep 30, 2024 | $26.57K | +330.6% |
| Q2 FY2024 | Jun 30, 2024 | $63.33K | – |
| Q1 FY2024 | Mar 31, 2024 | $147.38K | – |
| Q4 FY2023 | Dec 31, 2023 | $410.48K | – |
| Q4 FY2022 | Dec 31, 2022 | $6.17K | – |
See a number that looks wrong?